Besim Ogretmen

Has grant

Professor

Medical University of South Carolina
Country flagUnited States

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

About

Besim Ogretmen is an Associate Professor in the Department of Biochemistry and Molecular Biology at the Medical University of South Carolina in Charleston, USA. His research focuses on targeting sphingolipid metabolism as a therapeutic strategy in cancer treatment. With a commitment to advancing biomedical science, he contributes to the understanding of molecular mechanisms underlying cancer biology.

Recent Grants

Grant: Close

R01 and P01

Open Date:

Close Date:

Articles (7)

Year:

2026

Year:

2026

Patients with Alzheimer's disease (AD) have a decreased incidence of cancer, with a cross-sectional analysis of a nationwide sample of adults finding 21-fold higher odds of cancer diagnosis in non-AD individuals compared with those with AD. In this study, we demonstrated that mitochondrial localization of AD-associated amyloid-β precursor protein (APP) and its cleavage product amyloid-β 40, but not mutant APP that lacks a mitochondrial localization signal, inhibits lipid stress–mediated hyperactive mitophagy in aging T cells, improving their antitumor functions. Growth of melanoma xenograft or carcinogen-induced oral cancer models was highly reduced in AD mice. Additionally, adoptive cell transfer–based immunotherapy using aging T cells isolated from AD mice suppressed tumor growth. The metabolic signature of stress-dependent mitophagy in T cells showed fumarate depletion, which was linked to decreased succination of Parkin and enhanced mitochondrial damage. Mechanistically, APP interaction with the TOMM complex at the outer mitochondrial membrane attenuated trafficking of ceramide synthase CerS6 to mitochondria in aging AD T cells, preventing ceramide-dependent mitophagy. Thus, APP restored mitochondrial fumarate metabolism and Parkin succination, improving antitumor functions of AD T cells in vitro and in vivo . Exogenous fumarate supplementation or healthy AD mitochondria transfer functionally mimicked the AD/APP phenotype in aging T cells, enhancing their antitumor activity to control tumor growth. Moreover, T cells isolated from aging donors showed elevated mitophagy with fumarate depletion, which was restored in T cells isolated from age-matched patients with AD. Together, these findings show that AD protects T cells against ceramide-dependent mitophagy and fumarate depletion to enhance antitumor functions. Significance: The reduced cancer risk in Alzheimer's disease patients is mediated by the amyloid-β 40 peptide, which inhibits aging-dependent mitophagy in T cells to improve antitumor immunity. See related commentary by Bieberich, p. 3579

Year:

2025

Bioactive ceramide induces cell death in part by promoting mitophagy. C18-ceramide levels are commonly reduced in head and neck squamous cell carcinoma, which correlates with poor prognosis, suggesting the potential of harnessing ceramide for cancer treatment. In this study, we evaluated the ability of the ceramide analog D-erythro-14-(1-pyridinium)-N-octadecanoyl-sphingosine selenite (LCL768) to induce mitophagy and metabolic stress in head and neck squamous cell carcinoma. Mechanistically, LCL768 induced ceramide synthase 1 (CerS1)–mediated endogenous C18-ceramide accumulation in mitochondria to mediate mitophagy, which did not require the CerS1 transporter p17/PERMIT but was dependent on DRP1 activation via nitrosylation at C644. DRP1 facilitated the anchoring of the endoplasmic reticulum (ER) and mitochondrial membranes by promoting the association between phosphatidylethanolamine in the ER and cardiolipin in mitochondrial membranes. Mutations of Drp1 that prevented its binding to ER and mitochondrial membranes blocked CerS1/C18-ceramide mitochondrial accumulation, inhibiting LCL768-mediated mitophagy. In addition, LCL768-driven mitophagy altered mitochondrial metabolism, resulting in fumarate depletion and leading to tumor suppression in vivo . Exogenous fumarate supplementation prevented LCL768-mediated mitophagy, mitochondrial trafficking of CerS1, ER–mitochondrial tethering, and tumor suppression in mice. Fumarate metabolism was associated with PARKIN succination at a catalytic cysteine (Cys431), inhibiting its association with PINK1 and ubiquitin, thereby preventing mitophagy. LCL768-induced fumarate depletion attenuated PARKIN succination to promote PARKIN activation and mitophagy, indicating a feedforward mechanism that regulates mitophagy and fumarate metabolism through PARKIN succination. These data provide a mechanism whereby LCL768/CerS1-C18-ceramide–mediated mitophagy and tumor suppression are regulated by Drp1 nitrosylation, fumarate depletion, and PARKIN succination, providing a metabolic stress signature for lethal mitophagy. Significance: The identification of a metabolic link between ceramide-induced mitophagy, fission, and fumarate depletion reveals an effective tumor suppressive strategy for head and neck squamous cell carcinoma.

Year:

2025

Purpose: BXQ-350, a nanovesicle formulation of saposin C, is an allosteric sphingolipid metabolism regulator that increases proapoptotic ceramide and decreases oncogenic sphingosine-1-phosphate levels. We conducted a first-in-human phase I study of BXQ-350. Patients and Methods: Adults (≥18 years old) with advanced/recurrent, treatment-refractory solid tumors or high-grade gliomas received BXQ-350 intravenously in five dose cohorts (0.7–2.4 mg/kg) in a 3+3 dose escalation and expansion design. The primary endpoints during dose escalation were dose-limiting toxicities and maximum tolerated dose; the primary objective in expansion parts was assessment of antitumor activity (RECIST v1.1/Response Assessment in Neuro-Oncology criteria). Results: Eighty-six patients were enrolled. Dose-limiting toxicities were not observed during dose escalation ( n = 18), and a maximum tolerated dose was not identified. An additional 68 patients received the 2.4 mg/kg dose. Nine patients (10%) discontinued due to adverse events. The most common treatment-related adverse events were nausea (24%) and fatigue (23%). Eight patients had a progression-free survival of ≥ 6 months. Two of these achieved a partial response, and six had stable disease, among whom three had a reduction in ≥1 target lesion. Of those with progression-free survival of ≥6 months, seven remained on study for >12 months, five for >24 months, and after 7 years, two remained on study without disease progression. Conclusions: BXQ-350 was well-tolerated as monotherapy at doses up to 2.4 mg/kg. It provided some lasting clinical benefit in patients with recurrent solid malignancies across several tumor types, consistent with a decreased systemic sphingosine-1-phosphate/ceramide metabolic rheostat. BXQ-350 warrants further clinical investigation alone and combined with standard of care for advanced solid tumors.

Year:

2024

The metabolic consequences of mitophagy alterations due to age‐related stress in healthy aging brains versus neurodegeneration remain unknown. Here, we demonstrate that ceramide synthase 1 (CerS1) is transported to the outer mitochondrial membrane by the p17/PERMIT transporter that recognizes mislocalized mitochondrial ribosomes (mitoribosomes) via 39‐FLRN‐42 residues, inducing ceramide‐mediated mitophagy. P17/PERMIT‐CerS1‐mediated mitophagy attenuated the argininosuccinate/fumarate/malate axis and induced d ‐glucose and fructose accumulation in neurons in culture and brain tissues (primarily in the cerebellum) of wild‐type mice in vivo. These metabolic changes in response to sodium‐selenite were nullified in the cerebellum of CerS1to/to (catalytically inactive for C18‐ceramide production CerS1 mutant), PARKIN−/− or p17/PERMIT−/− mice that have dysfunctional mitophagy. Whereas sodium selenite induced mitophagy in the cerebellum and improved motor‐neuron deficits in aged wild‐type mice, exogenous fumarate or malate prevented mitophagy. Attenuating ceramide‐mediated mitophagy enhanced damaged mitochondria accumulation and age‐dependent sensorimotor abnormalities in p17/PERMIT−/− mice. Reinstituting mitophagy using a ceramide analog drug with selenium conjugate, LCL768, restored mitophagy and reduced malate/fumarate metabolism, improving sensorimotor deficits in old p17/PERMIT−/− mice. Thus, these data describe the metabolic consequences of alterations to p17/PERMIT/ceramide‐mediated mitophagy associated with the loss of mitochondrial quality control in neurons and provide therapeutic options to overcome age‐dependent sensorimotor deficits and related disorders like amyotrophic lateral sclerosis (ALS).

Year:

2023

Year:

2022

Collaborators (19)

Kumar Sambamurti

Professor

Medical University of South Carolina

UNITED STATES
View details

Özgür Şahin

Professor and SmartState Endowed Chair

Medical University of South Carolina

UNITED STATES
View details

Paramita Chakraborty

Research Assistant Professor

Medical University of South Carolina

UNITED STATES
View details

Natalia Oleinik

Res. Assistant Professor

Medical University of South Carolina

UNITED STATES
View details

Norma Frizzell

Professor

University of South Carolina

UNITED STATES
View details

Anne Noonan

Professor

The Ohio State University Comprehensive Cancer Center

UNITED STATES
View details

Onder Albayram

Assistant Professor

Medical University of South Carolina

UNITED STATES
View details

Trisha M. Wise-Draper

University of Cincinnati

UNITED STATES
View details

Alexander Alekseyenko

Professor

Medical University of South Carolina

UNITED STATES
View details

Shikhar Mehrotra

Medical University of South Carolina

UNITED STATES
View details

Christina Voelkel-Johnson

Professor

Medical University of South Carolina

UNITED STATES
View details

Robert Wesolowski

Assistant Professor

Ohio State University

UNITED STATES
View details

Kalyani Sonawane

Assistant Director of Data and Analytics

University of Texas School of Public Health

UNITED STATES
View details

Ashish Deshmukh

Professor

Medical University of South Carolina

UNITED STATES
View details

Xue-Zhong Yu

Professor

Medical College of Wisconsin

UNITED STATES
View details

Elizabeth Hill

Professor, Biostatistics Shared Resource Director

Medical University of South Carolina

UNITED STATES
View details

Lei Zheng

The University of Texas Health Science Center at Houston

UNITED STATES
View details

Vinay Puduvalli

Professor and Chair

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Junmin Peng

Member (Professor)

St. Jude Children's Research Hospital

UNITED STATES
View details